Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease
Stopped Slow recruitment
Conditions
- Interstitial Lung Disease
- Myopathy, Inflammatory
Interventions
- DRUG: Nintedanib 150 milligrams [Ofev]
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre